List of works - Claudia Fumarola

AMPK-independent down-regulation of cFLIP and sensitization to TRAIL-induced apoptosis by AMPK activators

scientific article

Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage

scientific article published in July 2005

Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands

scientific article

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation

scientific article published on 19 March 2016

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

scientific article published on 12 December 2012

Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress

scientific article published on 27 July 2006

Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line

scientific article published on November 2004

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells

scientific article published on 21 July 2020

Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines

scientific article published on February 2008

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines

scientific article

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling

scientific article published on 21 August 2013

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

scientific article published on 22 December 2020

Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism

scientific article published on 17 July 2017

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer

scientific article published on January 2013

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

scientific article

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification

scientific article (publication date: 2013)

Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways

scientific article published on 9 March 2018

New therapeutic strategies for malignant pleural mesothelioma

scientific article published on 15 July 2016

Novel Activity of a Synthetic Decapeptide Against Toxoplasma gondii Tachyzoites.

scientific article published on 20 April 2018

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

scientific article

Physico-chemical characterization and biological evaluation of two fibroin materials

scientific article

Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".

scientific article published on 28 January 2014

Synergistic activity of letrozole and sorafenib on breast cancer cells

scientific article

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer

scientific article published on 24 May 2014

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.

scientific article

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

List of works by Claudia Fumarola

AMPK-independent down-regulation of cFLIP and sensitization to TRAIL-induced apoptosis by AMPK activators

Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage

Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress

Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells

Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification

Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways

New therapeutic strategies for malignant pleural mesothelioma

Novel Activity of a Synthetic Decapeptide Against Toxoplasma gondii Tachyzoites.

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

Physico-chemical characterization and biological evaluation of two fibroin materials

Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".

Synergistic activity of letrozole and sorafenib on breast cancer cells

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC